Researcher.Life Logo

Expert Review of Pharmacoeconomics and Outcomes Research : Impact Factor & More

eISSN: 1744-8379pISSN: 1473-7167

Aims and Scope of Expert Review of Pharmacoeconomics and Outcomes Research

Expert Review of Pharmacoeconomics & Outcomes Research is a bimonthly peer-reviewed medical journal covering all aspects of pharmacoeconomics. It was established in 2001 and is published by Informa. The editor-in-chief is A. Bottomley (European Organisation for Research and Treatment of Cancer). Less

Key Metrics

CiteScore
3.4
H-Index
60
Impact Factor
< 5
SJR
Q2Health Policy
SNIP
0.9
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Expert Review of Pharmacoeconomics and Outcomes Research

Expert Review of Pharmacoeconomics and Outcomes Research Journal Specifications

Overview
Publisher TAYLOR & FRANCIS LTD
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year2001
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Expert Review of Pharmacoeconomics and Outcomes Research ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Expert Review of Pharmacoeconomics and Outcomes Research

Universal school-based mental health promotion in Vietnam: a critical appraisal of a health-economic evaluation
  • 9 Aug 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
Comparative landscape of artificial intelligence-assisted systematic literature reviews
  • 9 Aug 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
Single versus multiple inhaler triple therapy in COPD using data from the pragmatic INTREPID trial: cost-effectiveness analysis from the Chilean public healthcare system perspective
  • 9 Aug 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
The economic burden of MASH: comparison of healthcare resource utilization and costs in patients with probable MASH, without MASH, and with diagnosed MASH.
  • 30 Jun 2026
  • Expert review of pharmacoeconomics & outcomes research
TENS in chronic pain management: a 11-year nationwide analysis using the French National Health Data System
  • 27 Jun 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
Real-world direct medical costs and resource utilization of immune checkpoint inhibitors in advanced NSCLC with COPD: a multicenter cost-consequence analysis from Iraq
  • 27 Jun 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
Universal school-based mental health promotion in Vietnam: a critical appraisal of a health-economic evaluation
  • 9 Aug 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
Comparative landscape of artificial intelligence-assisted systematic literature reviews
  • 9 Aug 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
Single versus multiple inhaler triple therapy in COPD using data from the pragmatic INTREPID trial: cost-effectiveness analysis from the Chilean public healthcare system perspective
  • 9 Aug 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
The economic burden of MASH: comparison of healthcare resource utilization and costs in patients with probable MASH, without MASH, and with diagnosed MASH.
  • 30 Jun 2026
  • Expert review of pharmacoeconomics & outcomes research
TENS in chronic pain management: a 11-year nationwide analysis using the French National Health Data System
  • 27 Jun 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
Real-world direct medical costs and resource utilization of immune checkpoint inhibitors in advanced NSCLC with COPD: a multicenter cost-consequence analysis from Iraq
  • 27 Jun 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research

FAQs on Expert Review of Pharmacoeconomics and Outcomes Research